Electra Therapeutics Inc.
ETRA
NASDAQ10.37
USD
-0.31
- -
ISIN
US2848251060
CUSIP
284825106
Return %
Stock
S&P500
1Y
-21.74
15.01
3Y
-21.74
82.56
5Y
-21.74
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Quehuong Dong
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 230 E Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Sep 18, 2026
- Website
- electra-therapeutics.com
- Similar Companies
- Business
- Electra Therapeutics, Inc. is a clinical-stage biotechnology company that develops first-in-class antibody therapies targeting signal regulatory proteins (SIRP) for immune-mediated diseases and cancer. Founded in 2018 and headquartered in South San Francisco, California, the company focuses on therapies designed to selectively deplete pathological myeloid cells and activated T lymphocytes, with programs addressing immunology, inflammation, hematologic malignancies and rare hyperinflammatory disorders. Its lead product candidate, ELA026, is an anti-SIRP monoclonal antibody in a global pivotal Phase 2/3 study for secondary hemophagocytic lymphohistiocytosis (sHLH) and is also being evaluated for expansion into hematologic cancers; the pipeline also includes ELA822, a second SIRP-targeted program advancing toward clinical development for immunology and inflammation. The company’s operations and research and development activities are centered in South San Francisco, and it serves the biopharmaceutical market through development-stage product candidates rather than commercialized products. In the past 1 to 2 years, Electra has undergone major financing and strategic development changes, including an oversubscribed $183 million Series C financing announced in October 2025 that was co-led by Nextech and EQT Life Sciences, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital and existing investors. Proceeds from that round are intended to fund the registrational global Phase 2/3 trial of ELA026 in sHLH, support expansion into hematologic cancers and advance ELA822 into the clinic. In September 2026, the company also disclosed plans for a U.S. initial public offering to raise up to about $341.9 million to support continued development of its lead immunology asset and associated regulatory and commercial readiness activities. Electra is a member of the Star Therapeutics constellation.
Company News
Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 1,333,333 Shares of Stock
Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 1,333,333 Shares
Kinzey Capital Management: Electra Sets Nasdaq IPO Terms
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
Electra Therapeutics targets $977.6 million valuation in US IPO